Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study
Por:
Chen, AP, Coyne, GHO, Wolters, P, Martin, S, Farschtschi, S, Blanco, I, Chen, ZP, Darrigo, LG Jr, Eoli, M, Whittle, JR, Nishida, Y, Lamarca, R, de la Rosa, R, Adeyemi, A, Herrero, I, Llorente, N, Diede, SJ, Dombi, E and Wolkenstein, P
Publicada:
1 jun 2025
Resumen:
Filiaciones:
NCI, Div Canc Treatment & Diag, Dev Therapeut Clin, NIH, Bethesda, MD USA
NCI, Dev Therapeut Clin, Bethesda, MD USA
NCI, Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD USA
Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany
Hosp Germans Trias I Pujol, Clin Genet Dept, Barcelona, Spain
Sun Yat Sen Univ, Canc Ctr, Dept Neurosurg Neurooncol, State Key Lab Oncol South China, Guangzhou, Peoples R China
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil
Fdn IRCCS Inst Neurol Carlo Besta, Dept Expt Neurooncol, Milan, Italy
Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
Nagoya Univ Hosp, Dept Rehabil, Nagoya, Japan
Alexion, AstraZeneca Rare Dis, Barcelona, Spain
Alexion, AstraZeneca Rare Dis, Boston, MA USA
Merck & Co Inc, Rahway, NJ USA
Univ Paris Est Creteil UPEC, Univ Paris Est Creteil, Henri Mondor Hosp,Assistance Publ Hop Paris, AP HP,Dept Dermatol,Natl Referral Ctr Neurofibroma, Paris, France
Bronze
|